$6.33
0.80% yesterday
Nasdaq, Oct 17, 10:00 pm CET
ISIN
US3722791098
Symbol
GNFT
Sector
Industry

Genfit SA Sponsored ADR Stock price

$6.33
+2.10 49.65% 1M
+2.70 74.38% 6M
+2.48 64.42% YTD
+3.22 103.54% 1Y
+2.63 71.13% 3Y
-8.47 57.23% 5Y
-13.99 68.85% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
+0.05 0.80%
ISIN
US3722791098
Symbol
GNFT
Sector
Industry

Key metrics

Market capitalization $315.28m
Enterprise Value $321.87m
P/E (TTM) P/E ratio 13.07
EV/Sales (TTM) EV/Sales 3.91
P/S ratio (TTM) P/S ratio 3.83
P/B ratio (TTM) P/B ratio 3.04
Revenue growth (TTM) Revenue growth 243.10%
Revenue (TTM) Revenue $82.22m
EBIT (operating result TTM) EBIT $17.52m
EPS (TTM) EPS $0.48
P/E forward 57.72
P/S forward 3.11
EV/Sales forward 3.18
Short interest 0.14%
Show more

Is Genfit SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Genfit SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Genfit SA Sponsored ADR forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Genfit SA Sponsored ADR forecast:

Buy
100%

Financial data from Genfit SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
82 82
243% 243%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
16% 16%
24%
- Research and Development Expense 42 42
7% 7%
51%
19 19
148% 148%
23%
- Depreciation and Amortization 1.62 1.62
10% 10%
2%
EBIT (Operating Income) EBIT 18 18
142% 142%
21%
Net Profit 24 24
167% 167%
29%

In millions USD.

Don't miss a Thing! We will send you all news about Genfit SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genfit SA Sponsored ADR Stock News

Neutral
GlobeNewsWire
25 days ago
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission has conditionally approved Iqirvo®1 (elafibranor) 80mg tablets for the treatment of ...
Neutral
GlobeNewsWire
3 months ago
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Age...
Neutral
GlobeNewsWire
3 months ago
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
More Genfit SA Sponsored ADR News

Company Profile

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.

Head office France
CEO Pascal Prigent
Employees 159
Founded 1999
Website www.genfit.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today